LYNNWOOD, Wash., July 17,
2024 /PRNewswire/ -- Volpara Health Technologies
Ltd., a leader in cancer detection software, announces key
executive changes to enhance customer success and drive growth.
Craig Hadfield is now Chief Customer
and Financial Officer (CCFO), and Becky
Weber joins as Executive Vice President of Sales. Following
Lunit's strategic acquisition of Volpara in May 2024, Teri
Thomas has been named Chief Business Officer of Lunit's
Cancer Screening Group while continuing as CEO of Volpara.
"The promotion of Craig Hadfield
to CCFO and the appointment of Becky
Weber as EVP of Sales align Volpara around creating
compelling customer value and driving revenue growth," said Volpara
CEO and Lunit CBO Teri Thomas. "Our new partnership with Lunit
enables us to grow and evolve our leadership team around key
business priorities. By delivering a customer-connected experience
unlike any others in our industry, we create a cycle where
satisfied customers drive more revenue and foster further
innovation."
Craig Hadfield -
Chief Customer and Financial Officer (CCFO)
Craig Hadfield, formerly Chief
Financial Officer at Volpara Health, now takes on the expanded role
of Chief Customer and Financial Officer, underscoring Volpara's
focus on compelling customer value, and linking financial
leadership with customer relationship enhancement. Craig has
relocated from New Zealand to
Seattle to deeply engage with
Volpara's extensive customer base in the US. He will continue
leading finance while overseeing customer operations.
Becky Weber -
Executive Vice President of Sales
Becky Weber joins Volpara as
Executive Vice President of Sales, bringing over 15 years of health
tech experience from Epic, Apple, Able Health, and Health Catalyst.
At Apple, she developed cutting-edge health apps for WatchOS. Becky
also has an extensive track record of partnering with prominent
healthcare institutions to achieve their population health and
revenue objectives, all while ensuring exceptional customer
experiences. Becky's role at Volpara will center on driving sales
strategies and expanding market presence, leveraging her extensive
customer engagement background to foster growth and innovation.
"By acquiring Volpara, Lunit has created a powerhouse in
AI-driven cancer detection and care," said Thomas. "The multiply
effect of combining Lunit's AI technology with Volpara's
established presence in breast cancer screening expertise enables
us to deliver superior cancer screening solutions, elevate customer
care and promote mutual growth."
About Volpara Health
Volpara Health is on a mission to save families from cancer with
AI-powered software that helps healthcare providers better
understand cancer risk, guide personalized care decisions, and
recommend additional imaging and interventions. Used in over 2,000
facilities by more than 5,600 technologists worldwide. Volpara's
software impacts nearly 17M patients,
supports over 3M annual cancer risk
assessments, and integrates seamlessly with electronic health
records and imaging systems. Volpara helps radiologists quantify
dense breast tissue with precision and technologists produce
mammograms with optimal positioning, compression, and dose. Volpara
software also streamlines operations to ease compliance and
accreditation. Volpara was acquired by Lunit in 2024 and is
headquartered in Wellington, New
Zealand, with an office in Seattle. Volpara is the trusted partner of
leading healthcare institutions globally. For more information,
visit www.volparahealth.com.
About Lunit
Founded in 2013, Lunit is a medical AI company on a mission to
conquer cancer. We harness AI-powered medical image analytics and
AI biomarkers to ensure accurate diagnosis and optimal treatment
for each cancer patient. Our FDA-cleared Lunit INSIGHT suite for
cancer screening serves over 3,000 hospitals and medical
institutions across 40+ countries. Our clinical findings are
featured in top journals, including the Journal of Clinical
Oncology and the Lancet Digital Health, and presented at global
conferences such as the ASCO and RSNA. In 2024, Lunit acquired
Volpara Health Technologies, setting the stage for unparalleled
synergy and accuracy, particularly in breast health and screening
technologies. Headquartered in Seoul,
South Korea, with a global network of offices, Lunit leads
in medical AI innovation. Discover more at lunit.io
View original content to download
multimedia:https://www.prnewswire.com/news-releases/volpara-health-enhances-executive-team-to-focus-on-customer-success-and-growth-302199350.html
SOURCE Volpara Health, Inc.